# A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

> **NCT01759576** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 40 (actual)

## Conditions studied

- Renal Insufficiency
- Healthy

## Interventions

- **DRUG:** Canagliflozin (JNJ-28431754)

## Key facts

- **NCT ID:** NCT01759576
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2013-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01759576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01759576, "A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01759576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*